ABBOTT LABORATORIES · News & developments
Abbott Laboratories Stock: Is ABT Undervalued on Its $1.35 Billion Buyback Update?
Source: Yahoo FinanceNeutral
Abbott was reported to have provided a $1.35 billion buyback update. The headline does not specify the authorization’s remaining balance, execution pace, or whether the repurchases had already reduced diluted shares.
Why this matters
Repurchases can return capital and increase per-share cash flow or earnings when completed below intrinsic value. They also use cash that could otherwise reduce Abbott’s higher debt balance, so the net valuation benefit depends on timing, funding, and the actual share count reduction.